An FDA advisory committee stacked with members having financial ties to the peptide industry voted last week to recommend reclassifying six of seven popular but unproven peptides, allowing compounding pharmacies to sell them legally without prior safety or efficacy testing. The move, championed by Health and Human Services Secretary Robert F Kennedy Jr, leverages a regulatory loophole that exempts compounding pharmacies from full FDA oversight, potentially opening a multibillion-dollar market for untested treatments.
Kennedy’s Push and the ‘Wolverine Stack’
In a February podcast with Joe Rogan, Kennedy declared himself “a big fan of peptides” and promised to make them more accessible. Rogan, an avid user of the “Wolverine stack” (BPC-157 and TB-500), had complained about the difficulty of obtaining these injectable vials, often sold for “lab use only”. Kennedy blamed the Biden-era FDA for restricting access, calling the agency’s 2023 decision to designate nearly 20 peptides as “significant safety risk” (category two) “illegal”.
Last week’s pharmacy compounding advisory committee recommended moving six of seven peptides to category one, which allows compounding pharmacies to produce and sell them. The seventh peptide, 5-amino-1MQ, was not recommended for reclassification. The FDA will make a final decision after consulting with the United States Pharmacopeia.
Compounding Pharmacies: From Bespoke Care to Regulatory Haven
Compounding pharmacies originated to create personalized medications for patients with allergies or special needs. Historically, they operated under state board oversight, not federal FDA rules. However, as they scaled up in the 1990s, they began producing drugs in bulk without corresponding regulatory changes. A 2012 fungal meningitis outbreak from the New England Compounding Center killed 64 people and sickened over 750, prompting the FDA to create two categories: “outsourcing facilities” (subject to FDA inspection) and “traditional” compounding pharmacies (still exempt).
Despite this, oversight remains lax. As of July 2023, 81% of the 93 registered outsourcing facilities had not been inspected by the FDA. Errors such as tenfold dosing mistakes are more common at compounding pharmacies than at major drug manufacturers, according to toxicologist Dr James Watson.
The Peptide Boom and Financial Ties
The peptide industry’s alliance with Kennedy predates the committee vote. Mark Mikhail, CEO of a major compounding pharmacy, was appointed to the pro-Kennedy MAHA PAC in 2024, advocating for deregulation. Several committee members run clinics offering peptide treatments. During voting, career scientists overwhelmingly opposed reclassification but were outnumbered by industry-affiliated members.
Telehealth companies like Hims & Hers have already positioned themselves for the boom. Since Kennedy announced his intentions, Hims & Hers stock surged over 125%. The company told the Guardian its “senior medical advisers see meaningful potential in several peptide therapies” and that it manufactures all peptides in-house. Investment firms predict the peptide market could reach billions annually if the FDA formalizes the change.
Safety Concerns and Consumer Risks
Janet Woodcock, former FDA chief deputy commissioner, warned that reclassification is “not supposed to be a route for unapproved drugs to get into the market” and would “disrupt the societal pact that drugs will be studied to see if they work before they are marketed”.
Consumers, already exposed to aggressive marketing on podcasts and social media, may not realize these drugs lack FDA approval. Detroit-area pharmacist Mohammed Chammout said patients show him TikTok videos and ask, “Can I get this peptide? How do I buy it?” He noted that many patients have limited access to doctors and are desperate for solutions. “They see these things online [and think], ‘Oh my God, I can reverse my ageing,’” he said.
Even before the committee vote, Kennedy removed the peptides from category two in April, creating a legal gray area. Some smaller compounders have already begun production. A 27-year-old New York woman died in July after a botched injection of an anti-ageing peptide from an unlicensed practitioner, highlighting the dangers of an unregulated market.
What’s Next?
The FDA’s final decision will determine whether compounding pharmacies can legally sell these peptides. If approved, the market could explode, with companies like Hims & Hers and Noom ready to capitalize. However, the boom may be temporary: if peptides later prove safe and effective, large pharmaceutical companies could patent and mass-produce them, squeezing out compounders.
For now, patients are caught in what Chammout calls “the wild west”. “This is a way to get the peptides in the market and produce revenue off them without having the FDA legality behind it,” he said. “It’s like the wild west right now.”
